MRSN
Mersana Therapeutics, Inc.29.05
+0.46+1.59%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
145.19MP/E (TTM)
-Basic EPS (TTM)
-13.95Dividend Yield
0%Recent Filings
10-Q
Q3 FY2025 results
Mersana narrowed Q3 losses to $7.5M from $11.5M y/y, as collaboration revenue held at $11.0M despite GSK milestone offset by J&J and Merck declines, while R&D fell 17% to $12.2M and G&A dropped 36% to $6.3M on restructuring cuts. Cash burned to $56.4M after repaying $25M debt; op cash use slowed to $55.1M YTD (derived). Restructuring completed, slashing headcount 55% and axing internal pipeline. Signed merger with Day One November 12 for $25/share plus CVRs tied to Emi-Le milestones. Merger failure risks Nasdaq delisting.
8-K
Day One acquires Mersana
Day One Biopharma struck a deal to buy Mersana via tender offer and merger, paying $25 cash upfront per share plus CVRs worth up to $30.25 more on Emi-Le milestones and a collaboration trigger, valuing equity at $129M now and up to $285M total. Closing eyed by end-January 2026, pending tenders and approvals. Deal risks non-closure on conditions.
8-K
Mersana merger at $25/share + CVRs
Mersana Therapeutics struck a merger deal with Day One Biopharmaceuticals on November 12, 2025, via tender offer for $25.00 cash per share plus CVRs worth up to $30.25 on Emi-Le milestones. Board unanimously recommends tender; close eyed by end-January 2026 pending 50%+ tender and HSR clearance. Deal locks in upfront value. Risks include no CVR payouts if milestones miss.
8-K
Nasdaq compliance warning issued
Mersana Therapeutics received a Nasdaq notice on September 5, 2025, for failing to meet the $50.0 million minimum market value of listed securities rule. The company has 180 days, until March 4, 2026, to boost its MVLS above that threshold for ten straight business days. Delisting looms if unmet, though Mersana plans to explore options. No guarantees here.
8-K
Mersana Q2 results and Emi-Le progress
Mersana Therapeutics reported Q2 2025 financials, showing a $24.3 million net loss matching last year's while trimming R&D expenses to $16.2 million from $17.2 million amid restructuring. Enrollment surged past 45 patients in Emi-Le's Phase 1 expansion for post-topo-1 TNBC, with initial data slated for H2 2025. Cash stands at $77.0 million, funding operations into mid-2026; a 1-for-25 reverse stock split secured Nasdaq compliance. Restructuring costs hit $3.9 million, but enrollment accelerates.
ADAG
Adagene Inc.
1.90+0.23
BOLT
Bolt Biotherapeutics, Inc.
5.45+0.06
JANX
Janux Therapeutics, Inc.
14.65-0.47
MNPR
Monopar Therapeutics Inc.
71.47-3.65
MRKR
Marker Therapeutics, Inc.
1.27-0.12
MRUS
Merus N.V.
96.92+0.10
NRIX
Nurix Therapeutics, Inc.
18.84-0.17
RADX
Radiopharm Theranostics Limited
5.99-4.64
TCRX
TScan Therapeutics, Inc.
0.95-0.01
TIL
Instil Bio, Inc.
11.25+0.13